The drug discovery process has always been a problem for the pharmaceutical industry’s low rates of success, high expenses, and long-time frames. Quantum computing (QC) is being touted as a revolutionary advancement because of its unparalleled speed to carry out intricate multi molecular simulation and optimization. Unfortunately, its practical use has been suppressed due to the absence of proper hardware and the integration problems with traditional systems. Our solution is a quantum-classical pipeline for drug discovery. This pipeline utilizes machine learning (ML) for protein-ligand binding, drug property optimization, and even de novo drug design. In this paper we describe the pipeline, its components, the way it operates using NISQ devices, and the improvements it has in terms of accuracy and scalability (93.5% vs 78.2%) when compared with classical methods. Finally, we summarize how this can aid in modern drug discovery. It could significantly decrease the cost and timeline for pharmaceutical innovations.
The drug discovery process has always been a problem for the pharmaceutical industry’s low rates of success, high expenses, and long-time frames. Quantum computing (QC) is being touted as a revolutionary advancement because of its unparalleled speed to carry out intricate multi molecular simulation and optimization. Unfortunately, its practical use has been suppressed due to the absence of proper hardware and the integration problems with traditional systems. Our solution is a quantum-classical pipeline for drug discovery. This pipeline utilizes machine learning (ML) for protein-ligand binding, drug property optimization, and even de novo drug design. In this paper we describe the pipeline, its components, the way it operates using NISQ devices, and the improvements it has in terms of accuracy and scalability (93.5% vs 78.2%) when compared with classical methods. Finally, we summarize how this can aid in modern drug discovery. It could significantly decrease the cost and timeline for pharmaceutical innovations.
The integration of quantum computing in drug discovery has the potential to revolutionize pharmaceutical research by significantly enhancing molecular simulations, drug screening, and optimization processes. Traditional computational methods often struggle with the complexity of molecular interactions, leading to high costs and extended timelines in drug development. Quantum computing, with its ability to process complex calculations exponentially faster than classical computers, offers innovative solutions to these challenges. This chapter explores the fundamentals of quantum computing, its application in pharmaceutical research, and real-world case studies from leading organizations. It also discusses existing challenges, potential solutions, and future directions for adopting quantum computing in drug discovery. By addressing key technical, ethical, and regulatory aspects, this chapter provides a comprehensive analysis of how quantum technologies can accelerate and optimize the drug discovery pipeline.
The integration of quantum computing and artificial intelligence (AI), collectively termed Quantum AI, is revolutionizing the pharmaceutical industry by reshaping the paradigms of drug discovery and development. Traditional approaches to drug design are often limited by high costs, extensive timelines, and the computational intractability of simulating complex molecular interactions. Quantum computing offers exponential processing power, enabling the accurate modeling of quantum-level chemical phenomena that classical computers struggle to handle. Concurrently, AI contributes by enhancing data interpretation, prediction of molecular behaviors, and pattern recognition across large biological datasets. Together, Quantum AI enables faster identification of drug candidates, improved simulation of drug-target interactions, and early prediction of pharmacokinetics and toxicity. Key quantum algorithms, such as the Variational Quantum Eigensolver (VQE) and quantum-enhanced machine learning, have demonstrated potential to outperform conventional methods in quantum chemical calculations. Moreover, this synergy facilitates personalized medicine by integrating patient-specific data to optimize therapeutic outcomes. Despite current challenges related to hardware scalability, algorithm optimization, and ethical integration, the future trajectory of Quantum AI is poised to redefine pharmaceutical innovation. This review underscores the transformative capabilities of Quantum AI and its potential to usher in a new era of efficient, cost-effective, and precision-driven drug development.
Early-stage decisions in the pharmaceutical development process carry outsized consequences for eventual clinical success, yet the computational tools underpinning these decisions remain fundamentally constrained. Computer-aided drug design (CADD) has transformed how researchers navigate chemical space and predict ligand–target interactions, but classical implementations rely on mechanical force-field approximations that fail to capture polarisation, charge transfer, and electron correlation effects central to molecular recognition and reactivity. Quantum-mechanical treatments that correctly describe these phenomena scale exponentially with system size on classical hardware, rendering them impractical for drug-relevant biomolecules. Quantum computing offers a physically motivated path beyond this scaling barrier: by exploiting superposition, entanglement, and interference, quantum algorithms can in principle simulate electronic structure with polynomial resource requirements for targeted problem classes. This article provides a theoretical review of how quantum computation integrates throughout the drug discovery pipeline, from target identification to lead optimisation. Its primary contribution is a pipeline-level mapping of quantum methods—including the Variational Quantum Eigensolver (VQE), quantum machine learning, and quantum-enhanced optimisation—to specific drug development stages. The review critically distinguishes near-term NISQ (Noisy Intermediate-Scale Quantum: current devices with 50–1,000 noisy qubits operating without full error correction) capabilities from fault-tolerant quantum computing (FTQC) requirements, quantifies current resource gaps through a worked CYP3A4 case study, and identifies algorithmic limitations (barren plateaus, ansatz expressibility, measurement overhead), hardware scalability, and error correction overhead as the principal barriers to practical deployment.
Drug development remains a complex, time-intensive, and costly process, with high failure rates in clinical trials. The advent of quantum computing presents promising opportunities to transform pharmaceutical research and development through enhanced molecular simulations and structure-based drug design. Quantum computing uses quantum mechanical phenomena like superposition and entanglement to process complex molecular interactions more efficiently than classical computers. The integration of quantum computing with machine learning algorithms has enabled more accurate predictions of drug-target interactions and improved virtual screening of compound libraries. Applications include structure-based drug design, molecular docking, lead optimization, and drug repurposing. Notable progress has been made through collaborations between pharmaceutical companies and quantum computing firms, demonstrating practical implementations in drug discovery workflows. However, several challenges persist, including hardware limitations, algorithmic maturity, skilled workforce gaps, and regulatory considerations. The combination of quantum computing with classical computing and machine learning approaches offers a hybrid framework that maximizes the strengths of each technology. As quantum computing technology advances, it is positioned to significantly impact pharmaceutical research and development, potentially reducing development timelines and improving success rates in drug discovery. This review explains the principles, current applications, integration, and limitations of quantum computing in drug development
Quantum AI, the integration of quantum computing and artificial intelligence, is revolutionizing drug design by addressing the limitations of traditional pharmaceutical development. This review explores its transformative potential in enhancing molecular simulations, structure-based, target-based, and ligand-based drug discovery, and personalized medicine. Quantum computing leverages principles like superposition, entanglement, and interference to perform complex calculations exponentially faster than classical systems, enabling precise modeling of molecular interactions. Algorithms such as the Variational Quantum Eigensolver (VQE) and Quantum Phase Estimation (QPE) outperform classical methods like Density Functional Theory (DFT) in accuracy and efficiency, facilitating the identification of promising drug candidates and optimizing their pharmacokinetic properties. Quantum AI also enhances personalized medicine by analyzing vast genomic datasets to tailor treatments, improving efficacy and minimizing adverse effects. Despite challenges, including noisy intermediate-scale quantum (NISQ) device limitations and the need for advanced error correction, ongoing research and interdisciplinary collaboration are driving progress. Quantum AI promises to reduce development costs, accelerate drug discovery, and democratize access to life-saving medications. By enabling simulation-based discovery and expanding drug-candidate libraries to include peptides and antibodies, it paves the way for breakthroughs in treating complex diseases. This review underscores the need for continued investment in quantum technology to fully harness its potential, positioning the pharmaceutical industry for a future where drug development is faster, more precise, and patient-centric, ultimately improving global healthcare outcomes.
INTRODUCTION: Quantum computing represents a transformative advancement in computational science, with applications in drug discovery, molecular interaction simulation, drug-target binding optimization, and the analysis of complex biological data at unprecedented speeds and accuracy. Quantum computing emerges as a powerful tool to accelerate the development of new therapeutics, drug design, and the simulation of complex chemical interactions, including personalized medicine strategies. The objective of this study is to explore the potential of quantum computing in drug discovery and development, highlighting its ability to reduce time and costs while accelerating the identification of promising drug candidates. METHODS: Quantum computing algorithms, such as Grover's algorithm and the Variational Quantum Eigensolver (VQE), are utilized to simulate molecular interactions of drugs and optimize drug design. In case studies, such as IBM's use of VQE for molecular simulations, these technologies demonstrate their effectiveness. RESULTS: Quantum computing has shown promise in addressing several technological barriers, such as lengthy development timelines and high costs. Additionally, demonstrated success in molecular simulations and solving challenges during the drug development process. However, challenges related to error rates, qubit coherence, and regulatory compliance remain. DISCUSSION: This study examines the applications of quantum computing in drug discovery, highlighting key techniques such as quantum simulation, quantum machine learning, and optimization algorithms. Quantum computing is crucial for interdisciplinary collaboration among quantum physicists, computational chemists, biologists, and pharmaceutical professionals, as it is essential to overcoming these obstacles and realizing the full potential of quantum technologies in medicine. CONCLUSION: Quantum computing holds great potential in drug discovery and development, offering accelerated, more accurate, and lower-cost research avenues, particularly in complex areas such as protein folding prediction and personalized medicine. This new paradigm has tremendous potential for guiding the future of pharmaceutical development and patient-focused medicine.